Category Archives: – Biotech

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

Posted on September 1, 2018 by admin

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

FDA CDER Director on Benlysta for lupus and adaptive clinical trials.

Posted on March 2, 2018 by admin

July 27, 2011- Janet Woodcock, MD, Director of the FDAs new drug division, CDER, discusses with Steven Greer,

Posted in - Biotech, - Pharma, FDA, Rheumatology | Leave a comment

Bending the cost curve of cancer care

Posted on February 26, 2018 by admin

May 25, 2011- Since the approval of Genentech’s costly Avastin in 2004, prominent oncologists have warned that

Posted in - Biotech, - Pharma, CMS, Oncology, VCU | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

Posted on January 2, 2018 by admin

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

This could be the best interview ever aired on Fox Business

Posted on November 15, 2017 by admin

August 15, 2017- by Steven E. Greer, MD Martin Shkreli was on Fox Business today, and the set seemed familiar. Ironically, I was in this same

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy | Leave a comment

Interview with the CEO of Galena Biopharma about cancer vaccines

Posted on November 5, 2017 by admin

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Oncology | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

Posted on September 9, 2017 by admin

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Interview with the CEO of Synthetic Biologics, Jeff Riley

Posted on September 1, 2017 by admin

February 8, 2016- Interviewed by Steven E. Greer, MD

Posted in - Biotech, Gastroenterology and liver, Infectious disease, NIH | Leave a comment

The Biggest Healthcare Stories of 2016

Posted on December 26, 2016 by admin

December 26, 2016- by Steven E. Greer, MD for The Healthcare Channel Policy changes dominated the 2016 year in healthcare news. There were few important new drug

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - The Weekly Summary, CMS, FDA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

Posted on November 1, 2016 by admin

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

The Biggest stories of 2015

Posted on October 20, 2016 by admin

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

The telomerase inhibitor Imetelstat developed by Geron

Posted on February 5, 2016 by admin

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

Posted on December 7, 2015 by admin

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry

Posted on September 25, 2015 by admin

September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking

Posted in - Biotech, - Pharma, Congress, FDA | Leave a comment

Actavis 1000% drug price hike: a case for healthcare reform

Posted on September 22, 2015 by admin

Update September 21, 2015- The Healthcare Channel was the first to report in 2009 on the business strategy of acquiring cheap generic drugs, cornering the market, then raising

Posted in - Biotech, - Generics, - Opinion, - Policy, CMS, Congress, FDA, Infectious disease | Leave a comment

The PCSK9 LDL drugs do not cut heart risk in half

Posted on March 18, 2015 by admin

March 18, 2015- Op-Ed by Steven E. Greer, MD The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data

Posted in - Biotech, - Opinion, Cardiac surgery, Cardiology, Primary care medicine | Leave a comment

New therapies for hepatitis C

Posted on November 6, 2013 by admin

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Super rapid acting insulin and inhaled insulin

Posted on September 9, 2013 by admin

September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University

Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

Posted on March 26, 2013 by admin

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

Posted on March 8, 2013 by admin

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment